delistings
Panadol Osteo decision could shift patients to opioids
Stakeholders have expressed disappointment in the PBAC’s restatement of its decision to delist Panadol Osteo, and concerns that patients may turn to stronger alternatives to manage their pain. The PBAC …
Apotex decision a warning bell
Apotex’ decision to pull two of its PBS-listed products should ring an alarm for the health and pharmaceuticals sector, says Belinda Wood, CEO of the Generic and Biosimilar Medicines Association. …
Apotex pulls products as price reductions bite
Apotex has announced that it will be ceasing supply of two PBS listed prescription products from its portfolio. The PBS delisting date is yet to be confirmed, and stock will …
Delistings, shortages looming as discount well runs dry
Pharmacy is set to see more delistings and stock shortages this year as a result of simplified price disclosure, GBMA president Belinda Wood warned over the weekend. Presenting at APP2016, …
Reconsider Panadol Osteo delisting in light of risks: Painaustralia
The PBS delisting of Panadol Osteo needs to be reconsidered in the light of cost and clinical safety implications, says Painaustralia. The organisation has highlighted the risk of adverse clinical …